Phase I Study of Image-Guided Radiation Concurrent With Double-Agent Chemotherapy for Hepatocellular Carcinoma
Image-Guided Radiation Therapy (IGRT) Associated With Concurrent Capecitabine and Oxaliplatin in the Treatment of Locally Advanced or Inoperable Hepatocellular Carcinoma (HCC): A Phase I Study
Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
A PHASE1 clinical study on Carcinoma, Hepatocellular, this trial is ongoing. The trial is conducted by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. and has accumulated 9 data snapshots since 2013. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE1
Status: Unknown Status → Unknown
-
Oct 2023 — Jul 2024 [monthly]
Unknown Status PHASE1
-
Dec 2022 — Oct 2023 [monthly]
Unknown Status PHASE1
-
Jan 2021 — Dec 2022 [monthly]
Unknown Status PHASE1
▶ Show 4 earlier versions
-
Jan 2019 — Jan 2021 [monthly]
Unknown Status PHASE1
-
Jun 2018 — Jan 2019 [monthly]
Unknown Status PHASE1
-
Feb 2018 — Jun 2018 [monthly]
Unknown Status PHASE1
Status: Recruiting → Unknown Status
-
Jan 2017 — Feb 2018 [monthly]
Recruiting PHASE1
First recorded
Sep 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Chinese Academy of Medical Sciences
- Sanofi
For direct contact, visit the study record on ClinicalTrials.gov .